34
Participants
Start Date
September 30, 2004
Primary Completion Date
January 31, 2009
Study Completion Date
January 31, 2009
aldesleukin
high dose: 720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days (maximum 5 doses) or low dose: 250,000 IU/kg subcutaneously daily for 5 days, after a two day rest, 125,000 IU/kg subcutaneously daily for 5 days for five weeks (2 days rest per week)
filgrastim
10 mcg/kg/day daily subcutaneously until neutrophil count \>1x10\^9/1.
therapeutic tumor infiltrating lymphocytes
Lymphocytes that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient.
cyclophosphamide
60 mg/kg/day x 2 days intravenously over 1 hour
fludarabine phosphate
25 mg/m\^2/day intravenous piggyback daily over 15-20 minutes for 5 days
radiation therapy
Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda
NCI - Surgery Branch, Bethesda
National Cancer Institute (NCI)
NIH
National Institutes of Health Clinical Center (CC)
NIH